pfd-2 Antibody

Introduction to PFDN2 Antibody

The PFDN2 antibody targets prefoldin subunit 2 (PFDN2), a molecular chaperone critical for protein folding and stability. PFDN2 is a component of the prefoldin complex, which binds unfolded polypeptides and transfers them to cytosolic chaperonin (CCT/TRiC) for proper folding . This antibody is widely used in research to study PFDN2's role in cellular processes, including cytoskeletal organization and disease mechanisms.

2.1. Structure of PFDN2

• PFDN2 belongs to the prefoldin beta subunit family and forms a double beta-barrel structure with coiled-coil extensions .

• It binds nascent polypeptides to prevent misfolding and facilitates transfer to CCT/TRiC .

3.1. Experimental Use Cases

3.2. Functional Insights

• siRNA knockdown of PFDN2 reduces levels of other prefoldin subunits (e.g., MM-1α/PFD5), indicating interdependent stability .

• PFDN2-deficient cells show impaired cytoskeletal organization and protein aggregation .

4.1. Role in Protein Folding

PFDN2 is essential for folding actin and tubulin by stabilizing nascent polypeptides and delivering them to CCT/TRiC . Disruption of this process leads to cytoskeletal defects .

4.2. Disease Associations

• Cancer: Amplification of the 1q23.3-q24.1 locus (containing PFDN2) is linked to bladder cancer progression .

• Neurodegeneration: Reduced PFDN2 expression correlates with protein misfolding in cellular models .

Challenges in Antibody Validation

• Cross-reactivity: Non-specific bands observed in WB suggest potential off-target binding .

• Validation requirements: Rigorous testing across multiple platforms (e.g., knockout cell lines) is critical to confirm specificity .

Future Directions

• Investigate PFDN2’s role in viral infection mechanisms, given its chaperone activity .

• Develop therapeutic strategies targeting PFDN2 in cancers with 1q23.3-q24.1 amplification .